Q3 EPS Estimates for Oruka Therapeutics Cut by Wedbush

Key Points

• Wedbush analysts have reduced their Q3 2025 earnings estimate for Oruka Therapeutics, now forecasting a loss of ($0.51) EPS, down from a previous estimate of ($0.49).
• The current consensus for Oruka Therapeutics' full-year earnings is a loss of ($3.41) per share, with estimates for subsequent years also reflecting continued losses.
• Oruka Therapeutics' stock is currently trading at $15.00 following a recent drop of 2.2%, with a market cap of approximately $561.75 million.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities researchers at Wedbush lowered their Q3 2025 earnings per share estimates for Oruka Therapeutics in a research report issued on Tuesday, August 12th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.51) per share for the quarter, down from their prior estimate of ($0.49). Wedbush has a "Outperform" rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics' Q4 2025 earnings at ($0.45) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.30) EPS, FY2028 earnings at ($3.05) EPS and FY2029 earnings at ($3.80) EPS.

ORKA has been the subject of a number of other research reports. BTIG Research began coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating for the company. HC Wainwright restated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday. Finally, Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock traded down $0.69 during mid-day trading on Friday, reaching $14.56. 148,271 shares of the stock traded hands, compared to its average volume of 249,067. The business's 50-day moving average is $13.40 and its 200-day moving average is $11.53. The stock has a market capitalization of $545.29 million, a PE ratio of -5.18 and a beta of -0.35. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $52.32.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at approximately $343,000. Squarepoint Ops LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at approximately $236,000. Millennium Management LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at approximately $588,000. Geode Capital Management LLC boosted its stake in Oruka Therapeutics by 2,348.6% during the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock valued at $6,643,000 after buying an additional 328,434 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Oruka Therapeutics during the fourth quarter valued at approximately $54,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.